VSTM Stock Price - Verastem Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch

Infinity (INFI) incurs narrower-than-expected Loss in Q4 and expects to report data from the monotherapy expansion and combination dose escalation components of its pipeline candidate IPI-549.

Mar. 16, 2018 at 6:36 p.m. ET
on Zacks.com

Key events next week - healthcare (continued #1)

Mar. 16, 2018 at 10:26 a.m. ET
on Seeking Alpha

10-K: VERASTEM, INC.

Mar. 13, 2018 at 7:37 a.m. ET
on Edgar Online - (EDG = 10Q, 10K)

Premarket Gainers as of 9:05 am (03/08/2018)

Mar. 8, 2018 at 9:20 a.m. ET
on Seeking Alpha

Premarket analyst action - healthcare

Mar. 8, 2018 at 8:26 a.m. ET
on Seeking Alpha

3 Things In Biotech You Should Learn Today: February 9, 2018

Feb. 10, 2018 at 8:00 a.m. ET
on Seeking Alpha

Your Daily Pharma Scoop: Abeona Surges, Gilead Results, Biogen Setback

Feb. 8, 2018 at 8:00 a.m. ET
on Seeking Alpha

Biotech Forum Daily Digest For February 7th

Feb. 7, 2018 at 2:39 p.m. ET
on Seeking Alpha

Verastem submits U.S. marketing application for lead candidate duvelisib; shares ahead 7% premarket

Feb. 7, 2018 at 8:05 a.m. ET
on Seeking Alpha

Biotech Forum Daily Digest For January 5th

Feb. 5, 2018 at 11:27 a.m. ET
on Seeking Alpha

Biotech Stocks' Research Reports Released on TG Therapeutics, Trevena, Vanda Pharma, and Verastem

Apr. 25, 2018 at 7:10 a.m. ET
on PR Newswire - PRF

Verastem to Host Analyst and Investor Day on May 2, 2018

Apr. 23, 2018 at 7:00 a.m. ET
on BusinessWire - BZX

Analysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure -- Research Highlights Growth, Revenue, and Consolidated Results

Apr. 19, 2018 at 8:00 a.m. ET
on GlobeNewswire

Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr. 9, 2018 at 4:05 p.m. ET
on BusinessWire - BZX

FDA Accepts New Drug Application for Duvelisib and Grants Priority Review

Apr. 9, 2018 at 3:00 a.m. ET
on BusinessWire - BZX

Verastem to Present at the H.C. Wainwright Global Life Sciences Conference

Mar. 29, 2018 at 7:00 a.m. ET
on BusinessWire - BZX

Technical Perspectives on Biotech Stocks -- Tesaro, Trevena, Vanda Pharma, and Verastem

Mar. 27, 2018 at 6:15 a.m. ET
on PR Newswire - PRF

Verastem Updates Presentation Time for Oppenheimer & Co. Healthcare Conference

Mar. 14, 2018 at 4:05 p.m. ET
on BusinessWire - BZX

Verastem to Present at Upcoming Conferences

Mar. 14, 2018 at 7:00 a.m. ET
on BusinessWire - BZX

Verastem Reports Year-End 2017 Financial Results

Mar. 13, 2018 at 7:00 a.m. ET
on BusinessWire - BZX

Verastem Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar. 2, 2018 at 4:05 p.m. ET
on BusinessWire - BZX

Verastem to Present at the 30th Annual ROTH Conference

Feb. 26, 2018 at 7:00 a.m. ET
on BusinessWire - BZX

Quotidian Technical Highlights on Selected Biotech Stocks -- Tesaro, Trevena, Vanda Pharma, and Verastem

Feb. 21, 2018 at 6:10 a.m. ET
on PR Newswire - PRF

How CEO's of Biotech are Incentivized and What This Means for Investors

Feb. 13, 2018 at 10:30 a.m. ET
on PR Newswire - PRF

Research Report Identifies Ichor, TASER International, Premier, NuVasive, Verastem, and BLACKLINE INC with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

Feb. 9, 2018 at 7:35 a.m. ET
on GlobeNewswire

Blog Exposure - Verastem Reported Submission of NDA For Duvelisib for Treatment of Patients with Relapsed or Refractory CLL/SLL and Follicular Lymphoma

Feb. 9, 2018 at 7:11 a.m. ET
on ACCESSWIRE

Verastem Submits New Drug Application to U.S. FDA for Duvelisib for the Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma

Verastem Submits New Drug Application to U.S. FDA for Duvelisib for the Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma

Feb. 7, 2018 at 7:00 a.m. ET
on BusinessWire - BZX

Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb. 6, 2018 at 4:05 p.m. ET
on BusinessWire - BZX

Verastem Presents Preclinical Data at ASCO-SITC Highlighting the Synergistic Effects of Duvelisib in Combination with Immune Checkpoint or Co-Stimulatory Antibodies in B Cell Lymphoma Model

Jan. 26, 2018 at 2:45 p.m. ET
on BusinessWire - BZX

Stock Review for Biotech's Investors -- Ardelyx, Verastem, and Acceleron Pharma

Jan. 11, 2018 at 6:45 a.m. ET
on PR Newswire - PRF

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs to treat cancer by the targeted killing of cancer stem cells. Its product candidates include duvelisib, which targets the Phosphoinositide 3-kinase signaling pathway; and defactinib, a targeted inhibitor of the Focal Adhesion Kinase signaling pathway. It evaluates these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg and Christoph H. Westphal on August 4, 2010 and is headquartered in Cambridge, MA. (See Full Profile)